Integral BioSystems files more NanoM-Wafer patents as dry-eye device nears human studies

Integral BioSystems said its NanoM-Wafer Lubricating Bandage is nearing manufacturing and first-in-human studies, while the company filed additional patent cooperation treaty applications in major global jurisdictions. The device is being developed as a drug-free medical device for dry-eye symptoms and is slated for an initial launch in Europe.

Why it matters: - Integral BioSystems is trying to lock down broader intellectual property protection around a platform it sees as a base for multiple eye treatments. - The NanoM-Wafer Lubricating Bandage is moving toward manufacturing and first-in-human studies, bringing the dry-eye product closer to clinical validation. - The company is developing the platform as a drug-free medical device, which could broaden commercial use and regulatory positioning.

What happened: - Integral BioSystems filed additional extensive NanoM-Wafer™ patent cooperation treaty applications in major global jurisdictions. - The company said the original invention already has granted patents in Europe, the U.S., Canada, India, Indonesia, South Korea, Australia, New Zealand, China and Japan. - The company said the final composition and other developmental milestones for the first product are close to completion. - The first product is the NanoM-Wafer Lubricating Bandage. - The product is being readied for manufacturing and first-in-human studies. - The technology was presented at ARVO 2026 under the title, “Development of an In-Situ Forming Lubricating Ocular Bandage to Alleviate Symptoms of Dry Eye”.

The details: - The NanoM-Wafer Lubricating Bandage is designed to form an in-situ anchoring lubricating film on the ocular surface. - A dry wafer hydrates into a thin hydrogel after placement on the eye. - The hydrogel lasts 11-13 hours on the ocular surface. - The hydrogel surface-erodes to a Langmuir Blodgett-like monolayer at the air-water interface. - The product contains ophthalmologically compatible polymers, lipids and a hydration-enhancing excipient. - The formulation interacts with cells to stimulate tear mucin production. - The design replaces key components of the tear film in dry eye disease. - Rapid hydration turns the flexible wafer into a transparent, tissue-interlocking, tissue-conforming hydrogel. - The hydrating excipient helps resist further depletion of aqueous fluid and supports a highly hydrated microenvironment. - The device is being developed to treat symptoms of dry eye. - The company plans an initial introduction in Europe, followed by other countries. - The platform is being considered for other ocular products, including treatments for presbyopia, cystinosis and glaucoma. - Prototype testing in rabbit eye models showed safety and tolerability.

Between the lines: - The patent push suggests Integral BioSystems is trying to create a stronger moat around a platform that could be extended beyond dry eye. - The comparison to Lacrisert signals that the company is positioning NanoM-Wafer as a more advanced successor in the ocular insert category. - The emphasis on biomimetics and tissue-biomaterial interaction points to a strategy focused on retention, comfort and compatibility on the eye surface. - Integral BioSystems said it will license the platform to its spin-off company, Symphony Therapeutics, to help attract investor funding and pharma collaborations.

What's next: - Integral BioSystems is preparing the NanoM-Wafer Lubricating Bandage for manufacturing and first-in-human studies. - The company expects the first market introduction in Europe before expanding to other countries. - Integral BioSystems is seeking partners through its business development team at info@integralbiosystems.com. - The company is also advancing licensing plans for Symphony Therapeutics to support fundraising and collaboration efforts.

The bottom line: - Integral BioSystems is moving a drug-free dry-eye device closer to clinical testing while building a wider global patent fence around the platform.